Exploratory biomarkers and pharmacokinetic analysis
Cytogenetic analysis was performed for the all‐treated population who had one assessment on the biomarker of interest (collected from bone marrow and blood samples) unless otherwise specified.Immunophenotyping analysis was performed for part of the safety population, consisting of all patients who received at least one dose or a part of a dose of the study treatments during Phase 2.Blood samples were collected at selected time points over Cycle 1 to perform PK non‐compartmental analysis for Isa.Additional details can be found in Methods 